A start-up from Cambridge, Massachusetts within the US, has raised $114m (£87.4m) of funding to run human trials of a novel encapsulation machine designed to deal with type 1 diabetes. Semma Therapeutics has been based by celebrated Harvard researcher, Professor Doug...